

October 30, 2002

0475 02 09-0 11:34

Dockets Management Branch  
HFA-305  
Food and Drug Administration  
5630 Fishers Lane  
Room 1061  
Rockville, Maryland 20852

Re: 21 CIR Part 314  
Docket No. 02N-0417  
RIN 0910-AC48


Dear Sirs:

Thank you for the opportunity to comment on the above referenced document. Our nation's health care system is facing many problems at the present time. One of the issues involves the cost of prescription medication. Related to this is the effort of some manufacturers to keep patents on certain medications to prevent them from being issued as much cheaper generics. The Bush Administration has attempted to address this with these proposed regulations.

We agree with your decision to limit 30 month stays to one per ANDA.

This is a well written and needed rule and we look forward to its implementation.

Sincerely,



David Eichenauer

DE/se

02N-0417

C1